1. Home
  2. AHRT vs ALT Comparison

AHRT vs ALT Comparison

Compare AHRT & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AHRT

AH Realty Trust Inc. Common Stock

N/A

Current Price

$6.48

Market Cap

455.6M

Sector

Finance

ML Signal

N/A

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$3.09

Market Cap

421.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AHRT
ALT
Founded
1979
1997
Country
United States
United States
Employees
98
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
455.6M
421.5M
IPO Year
2013
2005

Fundamental Metrics

Financial Performance
Metric
AHRT
ALT
Price
$6.48
$3.09
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$7.00
$17.67
AVG Volume (30 Days)
620.4K
5.0M
Earning Date
05-04-2026
05-08-2026
Dividend Yield
9.30%
N/A
EPS Growth
N/A
25.37
EPS
N/A
N/A
Revenue
N/A
$41,000.00
Revenue This Year
$854.92
N/A
Revenue Next Year
$11.36
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
105.00
52 Week Low
$5.13
$2.56
52 Week High
$6.50
$7.73

Technical Indicators

Market Signals
Indicator
AHRT
ALT
Relative Strength Index (RSI) 65.90 47.28
Support Level $5.93 $2.87
Resistance Level N/A $4.23
Average True Range (ATR) 0.16 0.18
MACD 0.04 0.04
Stochastic Oscillator 98.28 53.68

Price Performance

Historical Comparison
AHRT
ALT

About AHRT AH Realty Trust Inc. Common Stock

AH Realty Trust Inc is a real estate investment trust (REIT). It owns, operates, and acquires high-quality properties across the Mid-Atlantic and Southeast, creating lasting value for investors, partners, clients, tenants, and communities. The group focuses on operating and acquiring high-quality, well-positioned assets with growth potential and delivering long-term value for shareholders. Its portfolio includes Harbor Point, Southern Post, The Interlock, and Others.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: